Skip to main content

Advertisement

Log in

Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma: Who, What, and When?

  • Lymphomas (PA Hamlin, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Secondary central nervous system (CNS) progression in patients with non-Hodgkin lymphoma (NHL) is associated with a particularly poor prognosis. In this review, we summarize and critically evaluate the current literature to guide the practicing clinician in estimating CNS relapse risk in order to select individual patients who may benefit from CNS prophylaxis, covering histologic subtype, anatomic location, and molecular and clinical factors. We summarize the data regarding different prophylaxis strategies used and provide our recommendation regarding who should receive it, what they should receive, and when it should be administered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Paper of particular of interest, published recently, have been highlighted as: •• Of major importance

  1. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13(7):1099–107.

    Article  CAS  PubMed  Google Scholar 

  2. Ferreri AJM, Assanelli A, Crocchiolo R, Ciceri F. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol. 2009;27(2):61–70. doi:10.1002/hon.881.

    Article  CAS  PubMed  Google Scholar 

  3. Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muniz C, et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2014;99(7):1228–35. doi:10.3324/haematol.2013.101741.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18(3):541–5. doi:10.1093/annonc/mdl434.

    Article  PubMed  Google Scholar 

  5. Aviles A, Jesus Nambo M, Neri N. Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center. Med Oncol. 2013;30(2):520. doi:10.1007/s12032-013-0520-0.

    Article  PubMed  Google Scholar 

  6. Mitrovic Z, Bast M, Bierman PJ, Bociek RG, Vose JM, Chan WC, et al. The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Br J Haematol. 2012;157(3):401–3. doi:10.1111/j.1365-2141.2011.08998.x.

    Article  CAS  PubMed  Google Scholar 

  7. Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011;90(7):809–18. doi:10.1007/s00277-010-1150-7.

    Article  CAS  PubMed  Google Scholar 

  8. Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2012;103(2):245–51. doi:10.1111/j.1349-7006.2011.02139.x.

    Article  CAS  PubMed  Google Scholar 

  9. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046–52. doi:10.1093/annonc/mdp432.

    Article  CAS  PubMed  Google Scholar 

  10. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178–84.

    PubMed  Google Scholar 

  11. Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. 2011;52(12):2270–5. doi:10.3109/10428194.2011.596966.

    Article  CAS  PubMed  Google Scholar 

  12. Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol. 2009;89(5):577–83. doi:10.1007/s12185-009-0289-2.

    Article  CAS  PubMed  Google Scholar 

  13. Yamamoto W, Tomita N, Watanabe R, Hattori Y, Nakajima Y, Hyo R, et al. Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol. 2010;85(1):6–10. doi:10.1111/j.1600-0609.2010.01438.x.

    CAS  PubMed  Google Scholar 

  14. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896–902. doi:10.1182/blood-2008-10-182253.

    Article  CAS  PubMed  Google Scholar 

  15. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129–33.

    Article  CAS  PubMed  Google Scholar 

  16. Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2013. doi:10.3109/10428194.2013.811239.

    Google Scholar 

  17. Nitta H, Terui Y, Yokoyama M, Mishima Y, Nishimura N, Ueda K, et al. Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma. Haematologica. 2015;100(1):87–90. doi:10.3324/haematol.2014.114934.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Schmitz N, Zeynalova S, Nickelsen M, Ziepert M, Pfreundschuh M, Glass B, et al. A new prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Hematol Oncol. 2013;31(S1):96–150. doi:10.1002/hon.2057. Abstract proposing the DSHNHL CNS prediction model.

    Article  Google Scholar 

  19. Savage KJ, Zeynalova S, Kansara RR, Nickelsen M, Villa D, Sehn LH, et al. Validation of a prognostic model to assess the risk of cns disease in patients with aggressive B-cell lymphoma. Blood (ASH Ann Meet Abstr). 2014;124(21):394. Validation of the DSHNHL CNS predicition model in an independent, uniformly treated cohort.

    Google Scholar 

  20. Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123(4):486–93. doi:10.1182/blood-2013-10-530659.

    Article  CAS  PubMed  Google Scholar 

  21. Sagoo MS, Mehta H, Swampillai AJ, Cohen VM, Amin SZ, Plowman PN, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59(5):503–16. doi:10.1016/j.survophthal.2013.12.001.

    Article  PubMed  Google Scholar 

  22. Kim MM, Dabaja BS, Medeiros J, Kim S, Allen P, Chevez-Barrios P, et al. Survival outcomes of primary intraocular lymphoma: a single-institution experience. Am J Clin Oncol. 2014. doi:10.1097/coc.0000000000000028.

    Google Scholar 

  23. Grigg AP, Connors JM. Primary adrenal lymphoma. Clin Lymphoma. 2003;4(3):154–60.

    Article  PubMed  Google Scholar 

  24. Hu R, Zhang R, Miao M, Zhu K, Yang W, Liu Z. Central nervous system involvement of primary renal lymphoma with diffuse large B-cell type lymphoma. Am J Case Rep. 2013;14:292–4. doi:10.12659/ajcr.889308.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev. 2006;20(6):319–32. doi:10.1016/j.blre.2006.02.001.

    Article  PubMed  Google Scholar 

  26. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol. 1990;8(3):141–5.

    Article  CAS  PubMed  Google Scholar 

  27. Jacobs C, Hoppe RT. Non-Hodgkin's lymphomas of head and neck extranodal sites. Int J Radiat Oncol Biol Phys. 1985;11(2):357–64.

    Article  CAS  PubMed  Google Scholar 

  28. Mian M, Capello D, Ventre MB, Grazio D, Svaldi M, Rossi A, et al. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study). Ann Hematol. 2013. doi:10.1007/s00277-013-1856-4.

    Google Scholar 

  29. Di Marco A, Campostrini F, Garusi GF. Non-Hodgkin lymphomas presenting with spinal epidural involvement. Acta Oncol. 1989;28(4):485–8.

    Article  PubMed  Google Scholar 

  30. Eeles RA, O'Brien P, Horwich A, Brada M. Non-Hodgkin's lymphoma presenting with extradural spinal cord compression: functional outcome and survival. Br J Cancer. 1991;63(1):126–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. McDonald AC, Nicoll JA, Rampling RP. Non-Hodgkin's lymphoma presenting with spinal cord compression: a clinicopathological review of 25 cases. Eur J Cancer. 2000;36(2):207–13.

    Article  CAS  PubMed  Google Scholar 

  32. Salvati M, Cervoni L, Artico M, Raco A, Ciappetta P, Delfini R. Primary spinal epidural non-Hodgkin's lymphomas: a clinical study. Surg Neurol. 1996;46(4):339–43. discussion 43-4.

    Article  CAS  PubMed  Google Scholar 

  33. Perry JR, Deodhare SS, Bilbao JM, Murray D, Muller P. The significance of spinal cord compression as the initial manifestation of lymphoma. Neurosurgery. 1993;32(2):157–62.

    Article  CAS  PubMed  Google Scholar 

  34. Lyons MK, O'Neill BP, Marsh WR, Kurtin PJ. Primary spinal epidural non-Hodgkin's lymphoma: report of eight patients and review of the literature. Neurosurgery. 1992;30(5):675–80.

    Article  CAS  PubMed  Google Scholar 

  35. Epelbaum R, Haim N, Ben-Shahar M, Ben-Arie Y, Feinsod M, Cohen Y. Non-Hodgkin's lymphoma presenting with spinal epidural involvement. Cancer. 1986;58(9):2120–4.

    Article  CAS  PubMed  Google Scholar 

  36. Rathmell AJ, Gospodarowicz MK, Sutcliffe SB, Clark RM. Localized extradural lymphoma: survival, relapse pattern and functional outcome. The Princess Margaret Hospital Lymphoma Group. Radiother Oncol. 1992;24(1):14–20.

    Article  CAS  PubMed  Google Scholar 

  37. Monnard V, Sun A, Epelbaum R, Poortmans P, Miller RC, Verschueren T, et al. Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2006;65(3):817–23. doi:10.1016/j.ijrobp.2006.01.002.

    Article  PubMed  Google Scholar 

  38. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006;76(6):473–80. doi:10.1111/j.1600-0609.2006.00644.x.

    Article  PubMed  Google Scholar 

  39. Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol. 1998;9(2):191–4.

    Article  CAS  PubMed  Google Scholar 

  40. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer. 2002;95(3):576–80. doi:10.1002/cncr.10699.

    Article  CAS  PubMed  Google Scholar 

  41. Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2013;55(3):509–14. doi:10.3109/10428194.2013.811239.

    Article  PubMed  Google Scholar 

  42. Gleeson M, Cunningham D, Hawkes EA, Qian W, Smith P, Chadwick N, et al. Risk of CNS relapse with diffuse large B-cell lymphoma (DLBCL) in the rituximab era: results from the UK NCRI R-CHOP 14 v 21 Trial. Blood (ASH Ann Meet Abstr). 2014;124(21):1723.

    Google Scholar 

  43. Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012;118(11):2944–51. doi:10.1002/cncr.26588.

    Article  CAS  PubMed  Google Scholar 

  44. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20–7.

    Article  CAS  PubMed  Google Scholar 

  45. Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766–72. doi:10.1200/jco.2010.31.4187.

    Article  CAS  PubMed  Google Scholar 

  46. Yun J, Kim SJ, Won JH, Choi CW, Eom HS, Kim JS, et al. Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: a Consortium for Improving Survival of Lymphoma (CISL) report. Leuk Res. 2010;34(9):1175–9. doi:10.1016/j.leukres.2010.02.010.

    Article  PubMed  Google Scholar 

  47. Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol. 2013;24(9):2236–44. doi:10.1093/annonc/mdt192.

    Article  CAS  PubMed  Google Scholar 

  48. Guo H-Y, Zhao X-M, Li J, Hu X-C. Primary non-Hodgkin’s lymphoma of the breast: eight-year follow-up experience. Int J Hematol. 2008;87(5):491–7. doi:10.1007/s12185-008-0085-4.

    Article  PubMed  Google Scholar 

  49. Fukuhara S, Watanabe T, Munakata W, Mori M, Maruyama D, Kim SW, et al. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. Eur J Haematol. 2011;87(5):434–40. doi:10.1111/j.1600-0609.2011.01679.x.

    Article  PubMed  Google Scholar 

  50. Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014. doi:10.1111/bjh.12753.

    PubMed Central  Google Scholar 

  51. Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Hematol Oncol. 2013;31(1):10–7. doi:10.1002/hon.2012.

    Article  CAS  PubMed  Google Scholar 

  52. Bekkenk MW, Postma TJ, Meijer CJ, Willemze R. Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma. Cancer. 2000;89(4):913–9.

    Article  CAS  PubMed  Google Scholar 

  53. Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol: Off J Am Soci Clin Oncol. 2007;25(21):3168–73. doi:10.1200/JCO.2006.08.2313.

    Article  Google Scholar 

  54. Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, et al. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci. 2010;101(6):1480–6. doi:10.1111/j.1349-7006.2010.01555.x.

    Article  CAS  PubMed  Google Scholar 

  55. Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol. 2004;127(2):173–83. doi:10.1111/j.1365-2141.2004.05177.x.

    Article  PubMed  Google Scholar 

  56. Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol. 2008;26(31):5134–6.

    Article  PubMed  Google Scholar 

  57. Ferreri AJ, Campo E, Ambrosetti A, Ilariucci F, Seymour JF, Willemze R, et al. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol. 2004;15(8):1215–21. doi:10.1093/annonc/mdh274.

    Article  CAS  PubMed  Google Scholar 

  58. Cheah CY, Oki Y, Westin JR, Turturro F. A clinician's guide to double hit lymphomas. Br J Haematol. 2014. doi:10.1111/bjh.13276.

    PubMed  Google Scholar 

  59. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–9. doi:10.1200/JCO.2011.41.0985.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327–40. doi:10.1097/PAS.0b013e3181cd3aeb.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335–42. doi:10.3324/haematol.11305.

    Article  PubMed  Google Scholar 

  62. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19(1):25–33. doi:10.1038/modpathol.3800500.

    Article  CAS  PubMed  Google Scholar 

  63. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891–901. doi:10.1111/bjh.12982.

    Article  CAS  PubMed  Google Scholar 

  64. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61. doi:10.1182/blood-2014-05-578963.

    Article  CAS  PubMed  Google Scholar 

  65. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–7. doi:10.1200/jco.2011.41.4342.

    Article  CAS  PubMed  Google Scholar 

  66. Savage KJ, Sehn LH, Villa D, Kansara RR, Mottok A, Ennishi D, et al. The impact of concurrent MYC BCL2 protein expression on the risk of secondary central nervous system relapse in diffuse large B-cell lymphoma (DLBCL). Blood (ASH Ann Meet Abstr). 2014;124(21):495.

    Google Scholar 

  67. Lowenthal DA, Straus DJ, Campbell SW, Gold JWM, Clarkson BD, Koziner B. AIDS-related lymphoid neoplasia. The memorial hospital experience. Cancer. 1988;61(11):2325–37. doi:10.1002/1097-0142(19880601)61:11<2325::AID-CNCR2820611130>3.0.CO;2-0.

    Article  CAS  PubMed  Google Scholar 

  68. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. New Eng J Med. 1997;336(23):1641–8. doi:10.1056/NEJM199706053362304.

    Article  CAS  PubMed  Google Scholar 

  69. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538–43. doi:10.1182/blood-2005-04-1437.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105(5):1891–7. doi:10.1182/blood-2004-08-3300.

    Article  CAS  PubMed  Google Scholar 

  71. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354(23):2431–42. doi:10.1056/NEJMoa055759.

    Article  CAS  PubMed  Google Scholar 

  72. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003;4(1):22–9.

    Article  CAS  PubMed  Google Scholar 

  73. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319–31. doi:10.1182/blood-2010-09-297879.

    Article  CAS  PubMed  Google Scholar 

  74. Boulanger E, Gérard L, Gabarre J, Molina J-M, Rapp C, Abino J-F, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23(19):4372–80. doi:10.1200/jco.2005.07.084.

    Article  PubMed  Google Scholar 

  75. Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003;21(21):3948–54. doi:10.1200/jco.2003.06.013.

    Article  PubMed  Google Scholar 

  76. Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011;35(12):1571–7.

    Article  PubMed  Google Scholar 

  77. Ustun C, Reid-Nicholson M, Nayak-Kapoor A, Jones-Crawford J, McDonald K, Jillella AP, et al. Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome. Ann Hematol. 2009;88(4):351–8. doi:10.1007/s00277-008-0601-x.

    Article  PubMed  Google Scholar 

  78. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51(11):2047–53. doi:10.3109/10428194.2010.516040.

    Article  PubMed  Google Scholar 

  79. Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012;119(14):3245–55. doi:10.1182/blood-2011-08-373738.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15(4):1587–94.

    CAS  PubMed  Google Scholar 

  81. Ghesquieres H, Berger F, Felman P, Callet-Bauchu E, Bryon PA, Traverse-Glehen A, et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol. 2006;24(33):5234–41. doi:10.1200/JCO.2006.07.5671.

    Article  PubMed  Google Scholar 

  82. Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601–7. doi:10.1093/annonc/mdq627.

    Article  CAS  PubMed  Google Scholar 

  83. Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013. doi:10.1093/annonc/mdt139.

    PubMed  Google Scholar 

  84. Conconi A, Franceschetti S, Lobetti-Bodoni C, Stathis A, Bruna R, Riccomagno P, et al. Central nervous system (CNS) relapse in a population of 143 patients (Pts) with mantle cell lymphoma (MCL) from two centers. ASH Ann Meet Abstr. 2011;118(21):2660.

    Google Scholar 

  85. Gill S, Herbert KE, Prince HM, Wolf MM, Wirth A, Ryan G, et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol. 2009;147(1):83–8. doi:10.1111/j.1365-2141.2009.07835.x.

    Article  PubMed  Google Scholar 

  86. Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol. 1999;78(3):145–9.

    Article  CAS  PubMed  Google Scholar 

  87. Valdez R, Kroft SH, Ross CW, Schnitzer B, Singleton TP, Peterson LC, et al. Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol. 2002;15(10):1073–9. doi:10.1097/01.MP.0000030088.28684.5B.

    Article  PubMed  Google Scholar 

  88. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015. doi:10.1093/annonc/mdv111

  89. Ellin F, Landström J, Jerkeman M, Relander T. Patterns of central nervous system relapse in peripheral T-cell lymphomas—population-based data from the Swedish Lymphoma Registry. vol 21. 2014.

  90. Yi JH, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, et al. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1636–43. doi:10.1093/annonc/mdq645.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  91. Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol. 2010;21(5):1058–63. doi:10.1093/annonc/mdp412.

    Article  CAS  PubMed  Google Scholar 

  92. Stein M, Farrar N, Jones GW, Wilson LD, Fox L, Wong RK, et al. Central neurologic involvement in mycosis fungoides: ten cases, actuarial risk assessment, and predictive factors. Cancer J. 2006;12(1):55–62.

    Article  PubMed  Google Scholar 

  93. Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood. 2000;95(7):2212–8.

    CAS  PubMed  Google Scholar 

  94. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114–9. doi:10.1200/JCO.2008.16.8021.

    Article  PubMed  Google Scholar 

  95. Cheah CY, Seymour JF, Dickinson M. Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma. Int J Hematol Oncol. 2014;3(3):189–201. doi:10.2217/ijh.14.15.

  96. Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2002;43(9):1783–8. doi:10.1080/1042819021000006475.

    Article  CAS  PubMed  Google Scholar 

  97. Grossman SA, Reinhard CS, Loats HL. The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J Neurooncol. 1989;7(4):319–28. doi:10.1007/BF02147089.

    Article  CAS  PubMed  Google Scholar 

  98. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284–9. doi:10.1182/blood-2003-02-0542.

    Article  CAS  PubMed  Google Scholar 

  99. Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283–90. doi:10.1002/cncr.25278.

    Article  PubMed  Google Scholar 

  100. Holte H, Leppä S, Björkholm M, Fluge Ø, Jyrkkiö S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24(5):1385–92. doi:10.1093/annonc/mds621.

    Article  CAS  PubMed  Google Scholar 

  101. Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111(6):1072–9. doi:10.1038/bjc.2014.405. One of two retrospective controlled studies in patients treated with rituximab and chemotherapy showing that the addition of high-dose systemic methotrexate reduces CNS relapse.

    Article  CAS  PubMed  Google Scholar 

  102. Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2014. doi:10.1111/bjh.13194. One of two retrospective controlled studies in patients treated with rituximab and chemotherapy showing that the addition of high-dose systemic methotrexate reduces CNS relapse.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Chan Yoon Cheah and John F. Seymour declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John F. Seymour.

Additional information

This article is part of the Topical Collection on Lymphomas

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cheah, C.Y., Seymour, J.F. Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma: Who, What, and When?. Curr Oncol Rep 17, 25 (2015). https://doi.org/10.1007/s11912-015-0450-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-015-0450-4

Keywords

Navigation